Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 663 participants.
Also called NCT05103332
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 663 participants
- Sponsor
- Registry
-
NCT05103332 -
2021-003776-13
-
- Other papers using this trial's data
- Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Estonia, Germany, Latvia, Lithuania, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05103332. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2023-12-11 (actual). Results posted on 2025-07-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
- Acronym
- KARDIA-2
- Condition
- Hypertension
- Intervention (Drug)
- Indapamide
- Intervention (Drug)
- Amlodipine
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Zilebesiran
- Lead sponsor
- Alnylam Pharmaceuticals
Record details
- Record id
cardio:ct-nct05103332- Content hash
965cfd22b090846859889288f9b130e69c32eac919ee3bd49a0c698a64de46d2